Avenzo Therapeutics

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing innovative oncology therapies for patients with a focus on treatments for serious diseases. Their lead drug candidate, AVZO-021, is a highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. This drug is currently being studied in a Phase 1 clinical trial across multiple sites in the US for the treatment of HR+/HER2- metastatic breast cancer and other advanced solid tumors.

Avenzo was co-founded in 2022 by Dr. Athena Countouriotis and Dr. Mohammad Hirmand, both of whom have extensive experience in the field of oncology. The company has a strong team of experienced professionals and has secured significant funding through a Series A-1 financing round that brought in nine new investors. They have also entered into an exclusive licensing agreement with Allorion Therapeutics to develop and commercialize AVZO-021 globally (excluding Greater China).

Avenzo Therapeutics offers a comprehensive benefits package that includes paid vacation, sick time, and holidays, as well as a winter closure. The company also has an onsite gym, demonstrating a commitment to employee well-being. However, specific details regarding remote work options or flexible work arrangements are not provided.

Avenzo Therapeutics offers a comprehensive benefits package that includes health insurance coverage for medical, dental, and vision, as well as a healthcare flexible spending account, dependent care flexible spending account, group life and accidental death and dismemberment insurance, a 401(k) with employer match, paid time off, and a winter closure. They also provide access to an onsite gym.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative oncology therapies that target cell cycle control to combat serious diseases and offer new treatment options for patients. They are committed to advancing a pipeline of potentially best-in-class oncology therapies, with a focus on selectively inhibiting cyclin-dependent kinase 2, an enzyme that is dysregulated in many cancers.

Avenzo Therapeutics fosters a collaborative and driven culture where team members are united by a common purpose: to develop oncology therapies that make a meaningful difference in the lives of patients. The company actively seeks passionate, collaborative, and determined individuals who are committed to this mission.

Avenzo Therapeutics emphasizes its commitment to building a diverse and inclusive team, highlighting the importance of fostering collaboration and determination among its employees. While the website lacks specific details about its diversity, equity and inclusion (DE&I) initiatives, it does state that they are "always on the lookout for exceptional talent," suggesting a broad commitment to welcoming individuals from various backgrounds and experiences.